Most Read Articles
Pearl Toh, 5 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Yesterday
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.
Audrey Abella, 14 Oct 2020
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.

High dietary nicotine intake lowers risk of Parkinson disease in women

12 Oct 2020

Greater consumption of dietary nicotine reduces the risk of Parkinson’s disease (PD) in women, results of a study have shown.

This study was based on never-smoker participants from two large prospective cohorts: the Nurses’ Health Study (n=31,615) and the Health Professionals Follow-up Study (n=19,523). These cohorts had available information on dietary nicotine intake from 1986 from validate food frequency questionnaires.

The investigators calculated dietary nicotine based on consumption of peppers, tomatoes, processed tomatoes, potatoes, and tea. Questionnaires were utilized to identify incident PD cases, which were subsequently confirmed by reviewing medical records. Cohort-specific hazard ratios (HRs) and pooled HR were calculated using Cox proportional hazard models and fixed-effects models, respectively.

A total of 601 incident PD cases (305 men and 296 women) were identified during 26 years of follow-up. The pooled HR after adjusting for potential covariates was 0.70 (95 percent confidence interval [CI], 0.51–0.94) for the highest vs lowest quintile of dietary nicotine intake. However, the inverse association was only observed in women (adjusted HR, 0.64, 95 percent CI, 0.42_0.96), not in men (adjusted HR, 0.77, 95 percent CI, 0.50–1.20).

Similar significant results in women were observed after further adjustments for environmental tobacco smoke exposure, family history of PD, and use of ibuprofen.

Notably, high peppers intake correlated with a lower risk of PD (adjusted HR for ≥5 times/week compared with ≤3 times/month, 0.49, 95 percent CI, 0.25–0.94) in women but not in men (adjusted HR, 1.04, 95 percent CI, 0.57–1.90).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 5 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Yesterday
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.
Audrey Abella, 14 Oct 2020
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.